PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Here's Why You Should Retain AmerisourceBergen Stock Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches. However, stiff competition remains a woe.
Cerner (CERN) Inks Deal With Finland Regional Leadership
by Zacks Equity Research
Cerner (CERN) collaborates with Finland regional leadership to help bring integrated health and care.
Varian Expands Access to Advanced Cancer Treatment With Ethos
by Zacks Equity Research
Varian's (VAR) Ethos Therapy used by Goshen Center for Cancer Care marks the expansion access to personalized cancer care.
The Zacks Analyst Blog Highlights: Mettler-Toledo, PerkinElmer, Waters and Bruker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mettler-Toledo, PerkinElmer, Waters and Bruker
HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q2.
PRA Health (PRAH) Inks Deal With Leukemia & Lymphoma Society
by Zacks Equity Research
PRA Health (PRAH) partners with LLS to bring new treatments for children with relapsed acute leukemia.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) continues to gain traction from Senza, its flagship platform, and R&D capabilities. However, stiff competition remains a woe.
Varian's Halcyon System to Bring Improved Care to Singapore
by Zacks Equity Research
Varian (VAR) strengthens its partnership Proton Therapy Pte as it brings improved care to Singapore through Halcyon system.
4 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is gaining from strong life science, pharmaceutical and academic end-market demand. Industry participants MTD, PKI, WAT and BRKR are set to gain from rising healthcare spending and exposure to developing economies like China and India.
NextGen Healthcare Introduces New Behavioral Health Suite
by Zacks Equity Research
NextGen Healthcare's (NXGN) new behavioral health suite aims to provide whole person care with support services for healthcare providers and clinicians.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter earnings reflect dismal segmental performance. However, it exceeded expectation as it witnessed faster-than-anticipated recovery.
Aurora Cannabis (ACB) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal fourth-quarter results likely to reflect solid prospects in the Canadian market.
Patterson Companies (PDCO) Q1 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Despite weak performance across Patterson Companies' (PDCO) Dental and Animal Health segments in the fiscal first quarter results, it benefited from aggressive cost savings measures.
Is PerkinElmer (PKI) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (PKI) Outperforming Other Computer and Technology Stocks This Year?
What's in Store for Patterson Companies' (PDCO) Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect sluggishness at Dental segment.
Here's Why You Should Invest in LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter performance is likely to reflect weak performance by CVI and CSI.
Price War in Coronavirus Test Space to Intensify Thanks to Abbott
by Urmimala Biswas
Most rapid antigen tests in the United States require an additional system, which is making the procedures more costly and complex.
Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription business segment performs impressively in Q2.
PerkinElmer (PKI) Down 0.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is PerkinElmer (PKI) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider PerkinElmer (PKI).
AMN Healthcare's Advanced Mobile App to Aid Travel Clinicians
by Zacks Equity Research
AMN Healthcare's (AMN) new version of AMN Passport will benefit travel clinicians.
Allscripts Enhances Healthcare Innovation With Patent Program
by Zacks Equity Research
Allscripts (MDRX) continues to advance healthcare innovation by earning five new application patents.
Here's Why You Should Hold on to DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY (XRAY) continues to gain traction from its solid focus on R&D leading to product innovation, which continues to be a key catalyst.
Here's Why You Should Invest in Fresenius Medical Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services.